Skip to main content
JCR Pharmaceuticals Co.,Ltd. logo

JCR Pharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 4552 ISIN · JP3701000006 LEI · 353800IMIU9CQ1DGOS14 T Manufacturing
Filings indexed 62 across all filing types
Latest filing 2016-02-12 Interim / Quarterly Rep…
Country JP Japan
Listing T 4552

About JCR Pharmaceuticals Co.,Ltd.

https://www.jcrpharm.co.jp/en/site/en/

JCR Pharmaceuticals is a global specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of treatments for rare and genetic diseases. The company's portfolio includes therapies for conditions such as growth disorders, Mucopolysaccharidosis II (Hunter syndrome), and Fabry disease. A primary area of innovation involves developing treatments for central nervous system (CNS) disorders by utilizing proprietary technology to deliver biotherapeutics across the blood-brain barrier. JCR also develops and sells regenerative medicine products, aiming to address complex healthcare challenges and provide new treatment options for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
四半期報告書-第41期第3四半期(2015/10/01-2015/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains comprehensive financial statements, including the balance sheet and management analysis for the third quarter of the 41st fiscal year. It is not an announcement or a certification, but the full report itself, fitting the definition of an Interim/Quarterly Report. 9M 2016
2016-02-12 Japanese
四半期報告書-第41期第2四半期(2015/07/01-2015/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese '四半期報告書' (Quarterly Report) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MD&A), and corporate information for the second quarter of the 41st fiscal period (April 1, 2015 to September 30, 2015). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2015
2015-11-12 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.